Saci-IO HR+: Randomized phase II study of sacituzumab govitecan with or without pembrolizumab in hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC)
NOT ENROLLING
Trial ID:
NCT04448886 Protocol # :
20-153
Phase
II
Disease Sites
Breast
Principal Investigator
Garrido-Castro, Ana, C.
Site Research Nurses
Bowers, Jordan
Brule, Maurice, N.
Campbell, Margaret
Caradonna, Lisa
Casella, Allison
Cronis, Charles, Lewis
Cung, Connie
Fleming, Norah, Michelle
Gentile, Alissa
Ginter, Lindsey
Hixon, Nicole, R.
Houghton, Nicole
Jeon, Maryangel, H.
Kasparian, Elizabeth
Kosinski, Michelle
Kuhlman, Rachel
Macauley, Colleen
Orechia, Meghan
Patel, Nikita
Piper, Audrey, L.
Quinn, Caroline
Roche, Kathleen, A.
Rutter, Morgan
Trial Description
Call 877-DF-TRIAL (877-338-7425) to learn more about this clinical trial, protocol #20-153
20-153